<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129441">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417000</url>
  </required_header>
  <id_info>
    <org_study_id>ADU-CL-01</org_study_id>
    <nct_id>NCT01417000</nct_id>
    <nct_alias>NCT01468870</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer</brief_title>
  <official_title>A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aduro Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aduro Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test the safety, immune response and efficacy of GVAX pancreas vaccine (with
      cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide)
      alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival in subjects receiving test treatments</measure>
    <time_frame>Up to five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety of the cyclophosphamide, GVAX Pancreas vaccine, and CRS-207 treatment regimen</measure>
    <time_frame>About 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the immune response</measure>
    <time_frame>About three years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclophosphamide (200 mg/m^2) D0 of Weeks 1, 4; GVAX pancreas vaccine (5 x 10e8 cells) D1 of Weeks 1, 4; CRS-207 (1 x 10e9 CFU) Weeks 7, 10, 13, 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclophosphamide (200 mg/m^2) D0 of Weeks 1, 4, 7, 10, 13, 16; GVAX pancreas vaccine (5 x 10e8 cells) D1 of Weeks 1, 4, 7, 10, 13, 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GVAX Pancreas</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CRS-207</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically proven malignant adenocarcinoma of the pancreas; measurable
             disease is not required. (Subjects with mixed histology will be included if the
             predominant component is adenocarcinoma. Subjects must have metastatic disease.)

          -  Have received or refused at least one chemotherapy regimen

          -  At least 18 years of age

          -  ECOG of 0 or 1

          -  Anticipated life expectancy of &gt;12 weeks

          -  For women and men of childbearing potential, a medically acceptable method of highly
             effective contraception (oral hormonal contraceptive, condom plus spermicide, or
             hormone implants) must be used throughout the study period and for 28 days after
             their final vaccine administration. (A barrier method of contraception must be
             employed by all subjects [male and female], regardless of other methods.)

          -  Be willing and able to give written informed consent, and be able to comply with all
             study procedures

          -  Have adequate organ function as defined by specified laboratory values

        Exclusion Criteria:

          -  Currently have or have history of certain study-specified heart, liver, kidney, lung,
             neurological, immune or other medical conditions

          -  Known history or evidence of brain metastases

          -  Have any evidence of hepatic cirrhosis or clinical or radiographic ascites

          -  Have clinically significant and/or malignant pleural effusion

          -  Known or suspected hypersensitivity to any component of GVAX Pancreas vaccine or
             CRS-207, or known allergy to both penicillin and sulfa

          -  Received an investigational product within 28 days of study treatment or planned to
             receive within 28 days after vaccine administration

          -  Used any systemic steroids within 28 days of study treatment

          -  Use more than 3 g/d of acetaminophen

          -  Prosthetic joint or other artificial implant or device that cannot be easily removed
             (there are some exceptions)

          -  Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring
             within 28 days prior to receiving study drug, or planned surgery requiring general
             anesthesia

          -  Infection with HIV or hepatitis B or C at screening

          -  Any immunodeficiency disease or immunocompromised state or active autoimmune disease
             or history of autoimmune disease requiring systemic steroids or other
             immunosuppressive treatment

          -  Be pregnant or breastfeeding

          -  Unable to avoid close contact with another individual known to be at high risk of
             listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during
             the course of CRS-207 treatment until completion of antibiotic regimen

          -  Conditions, including alcohol or drug dependence, intercurrent illness, or lack of
             sufficient peripheral venous access, that would affect the patient's ability to
             comply with study visits and procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung T Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center of Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13.</citation>
    <PMID>15365184</PMID>
  </reference>
  <reference>
    <citation>Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008 Mar 1;14(5):1455-63. doi: 10.1158/1078-0432.CCR-07-0371.</citation>
    <PMID>18316569</PMID>
  </reference>
  <reference>
    <citation>Le DT, Dubenksy TW Jr, Brockstedt DG. Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol. 2012 Jun;39(3):311-22. doi: 10.1053/j.seminoncol.2012.02.008. Review.</citation>
    <PMID>22595054</PMID>
  </reference>
  <reference>
    <citation>Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.</citation>
    <PMID>25584002</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 25, 2017</lastchanged_date>
  <firstreceived_date>August 10, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Cancer vaccine</keyword>
  <keyword>Listeria monocytogenes</keyword>
  <keyword>Listeria-based vaccines</keyword>
  <keyword>GVAX</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>T regulatory cells</keyword>
  <keyword>Heterologous Prime-Boost</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Mesothelin</keyword>
  <keyword>Pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
